Recent Updates
Recently added Catalysts

Prevnar 13

Phase 4

Pneumococcal Infections | Biologics | Infectious Disease |Pfizer, Inc.|Trials Updated: Jun 12, 2019

Prevnar 13 development status

Highest phase Phase 4 run by GlaxoSmithKline (NCT02072525)
Phase scored for PFEPhase 1
Registered trials 38 across 7 sponsors since Oct 2009

Prevnar 13 target and mechanism

ModalityBiologics

Also known as Prevenar 13™

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment104

FDA Designations

No designations recorded

Prevnar 13 clinical trials

Prevnar 13 · 1 trial · 1 indication

Phase 1 1
NCT03642847Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of AgePneumococcal Infections
COMPLETED104 Analytics
PHASE1COMPLETED
Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age
Pneumococcal InfectionsUnlock trial analytics

Study Endpoints

Primary Endpoints

Subjects reporting prompted local reactions within 14 days after vaccination (redness, swelling, and pain at the injection site).
14 days after vaccination
Subjects reporting prompted systemic events within 14 days after vaccination (fever, headache, fatigue, muscle pain, and joint pain).
14 days after vaccination
Subjects reporting adverse events (AEs) within 1 month after vaccination.
1 month after vaccination
Subjects reporting serious adverse events (SAEs) within 6 months after vaccination.
6 months after vaccination
Subjects reporting newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination.
6 months after vaccination

Secondary Endpoints

Immunogenicity
1 month after vaccination
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Prevnar 13ACTIVE_COMPARATOR13 valent Pneumococcal Conjugate
multivalent pneumococcal conjugate formulation 1EXPERIMENTALmultivalent pneumococcal conjugate formulation 1
multivalent pneumococcal conjugate formulation 2EXPERIMENTALmultivalent pneumococcal conjugate formulation 2

Interventions

NameTypeDescription
Prevnar 13BIOLOGICAL13 valent Pneumococcal Conjugate
multivalent pneumococcal conjugate formulation 1BIOLOGICALmultivalent pneumococcal conjugate formulation 1
multivalent pneumococcal conjugate formulation 2BIOLOGICALmultivalent pneumococcal conjugate formulation 2
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 49 Years
SexALL
Healthy VolunteersYes
Study Sites4

Inclusion Criteria: * Male or female Japanese subjects 18 to 49 years of age, defined as Japanese born in Japan, with both parents and 4 grandparents who wer born in Japan (family tree by history), and who have not lived outside of Japan for more than 5 years total (confirmed by passport or intervi...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Prevnar 13

What is Prevnar 13?

Prevnar 13 is a biologic vaccine developed by Pfizer for pneumococcal infections, a therapeutic area of infectious disease. It is also known as Prevenar 13. The product is studied in clinical trials that assess safety and immune response in healthy adult volunteers.

What is Prevnar 13 used for in pneumococcal infections?

Prevnar 13 is intended for pneumococcal infections, which are bacterial infections caused by Streptococcus pneumoniae. Its clinical program has evaluated safety and immunogenicity in Japanese adults 18 to 49 years of age. The recorded trial enrolled 104 healthy volunteers in the United States.

Who makes Prevnar 13?

Prevnar 13 is made by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the developer associated with the vaccine and its clinical program for pneumococcal infections.

What phase is Prevnar 13 in?

Prevnar 13 is recorded at Phase 1 in its clinical development for pneumococcal infections. The single listed trial is a completed Phase 1 study, and no active trials are currently listed for this program.

What clinical trials is Prevnar 13 in?

Prevnar 13 has been studied in trial NCT03642847, titled Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age. The Phase 1 trial was completed, enrolled 104 participants, was randomized, double blind, and active controlled, and took place in the United States.

Is Prevnar 13 the same as Prevenar 13?

Yes, Prevnar 13 is also known as Prevenar 13, sometimes written Prevenar 13. The two names refer to the same Pfizer vaccine for pneumococcal infections, so readers searching either name are looking at the same product and clinical program.